Related Experiment Video
Updated: May 9, 2026
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
Modern Management of Mantle Cell Lymphoma
Tobias Tix1, Anita Kumar2, Toby A Eyre3
1Department of Medicine III, LMU Hospital, Munich, Germany.
Summary
Mantle cell lymphoma (MCL) management is evolving with risk-adapted strategies. Novel targeted therapies and cellular approaches are improving outcomes for both frontline and relapsed disease.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Mantle cell lymphoma (MCL) is a heterogeneous B-cell malignancy with unpredictable prognosis.
- Current management involves risk stratification using prognostic tools and biological markers.
- Treatment strategies are adapting to patient characteristics, disease burden, and tumor biology.
Purpose of the Study:
- To review contemporary management strategies for Mantle Cell Lymphoma.
- To highlight the integration of prognostic tools and novel therapeutics.
- To discuss evolving treatment landscapes for frontline and relapsed/refractory MCL.
Main Methods:
- Literature review of recent clinical trials and guidelines for MCL management.
- Analysis of prognostic factors including MIPI, Ki-67, TP53 status, and morphology.
- Evaluation of novel therapeutic agents such as BTK inhibitors, BCL2 inhibitors, and cellular therapies.
Main Results:
- Dose-intensified chemoimmunotherapy with ASCT is standard for young, fit patients, with BTKi incorporation improving outcomes.
- Bendamustine-rituximab is a backbone for older/ineligible patients; chemotherapy-free options are emerging.
- Relapsed/refractory MCL is managed with BTKi, BCL2 inhibitors, and T-cell redirecting therapies; ongoing trials explore optimal sequencing.
Conclusions:
- Modern MCL management is individualized, based on biological risk, patient fitness, and treatment tolerance.
- Novel targeted and cellular therapies are transforming frontline and relapsed treatment paradigms.
- Optimizing sequencing and combinations of novel agents is crucial for improving MCL patient outcomes.
Related Concept Videos
01:22Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:19Mitral Valve Prolapse III: Nursing Management
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...